Draft monograph: PT-141 (bremelanotide) — disposition

§3Disposition and amendments

§3.1Disposition table

Table 1. Every submission with its disposition. Each row links to the submission in full.

§3.2Summary by disposition

Table 2. Counts by disposition, with the meaning of each.

§3.3Resulting amendments

1. The interaction section lists mechanisms rather than interactions — arising from DRAFT-PT-141-MONOG/001. The interaction section is now divided into interactions reported in clinical use and interactions predicted from mechanism, with the second labelled as prediction. Where neither exists the section says so in one line rather than being padded.
2. Effect estimates are given without naming the comparator — arising from DRAFT-PT-141-MONOG/002. The comparator is now stated in every outcome row, and estimates against different comparators are reported in separate tables with the comparator named in the table caption.
3. The absence of a rare harm in the trial set is presented as reassurance — arising from DRAFT-PT-141-MONOG/003. Wherever the monograph reports that an event was not observed, it now states the total exposure and the frequency the contributing trials could have detected, so that the absence is read as the limit of the evidence rather than as a finding.
4. Open-label extension data are presented alongside randomised data without distinction — arising from DRAFT-PT-141-MONOG/004. Extension data now appear in a separate table headed as uncontrolled follow-up, with a standing note on differential withdrawal.
5. Mechanistic claims for a peptide fragment are carried without evidence that the fragment acts as… — arising from DRAFT-PT-141-MONOG/005. Mechanistic claims not traceable to a primary source are removed, and those retained carry their source and a statement of whether the underlying work was conducted in vitro, in animals or in humans.
6. Regulatory status is stated without naming the jurisdiction — arising from DRAFT-PT-141-MONOG/006. Every regulatory status statement now names the authority, states the date on which the status was verified, and is recorded per jurisdiction rather than as a single global assertion.
7. The population to which the headline estimate applies is not stated with the estimate — arising from DRAFT-PT-141-MONOG/007. Every headline estimate now carries a one-line statement of the population in which it was observed, and the full eligibility criteria are reported in the included-studies table rather than only in the source.
8. Trials are described as terminated where they completed as planned — arising from DRAFT-PT-141-MONOG/008. Trial status now uses a fixed vocabulary defined in the glossary, and where the reason for stopping is not evidenced by a document the Institute holds, the status is recorded as stopped with the reason not established rather than assigned.
9. What happens when the compound is stopped is not addressed — arising from DRAFT-PT-141-MONOG/009. Discontinuation trajectory is now an assessed outcome in every monograph where a contributing trial measured it, and a recorded evidence gap in every monograph where none did, so that its absence is visible rather than silent.
10. Two factual descriptions of the sponsor's programme are inaccurate — arising from DRAFT-PT-141-MONOG/010. The trial status now reads as completed at a pre-specified interim analysis, with the analysis identified, and the dose is stated in the unit used in the approved labelling. The submission is identified as an industry submission on its face in accordance with…
11. Point estimates are given without an interval — arising from DRAFT-PT-141-MONOG/011. Every estimate now carries its interval where the source reported one, and where it did not, the estimate is annotated as reported without an interval rather than left to appear as a precise figure.
12. Registered trials that never reported are absent from the monograph — arising from DRAFT-PT-141-MONOG/014. The trial list now includes every registered trial the Institute identified, with its reporting status stated, and the monograph reports the proportion of registered trials for which no result has been posted or published.
13. Storage and reconstitution guidance is given without stating what it rests on — arising from DRAFT-PT-141-MONOG/015. In-use periods now appear only where supported by a cited stability determination on a stated presentation, and elsewhere the monograph records that no in-use stability evidence was identified for this presentation.
14. The monograph does not tell a reader that two vials of the same compound may not contain the same… — arising from DRAFT-PT-141-MONOG/016. A standing paragraph now appears at the head of §8 in every monograph, stating that a determination applies to the lot measured and that a label mass is not a determination.
15. The compound is supplied under names the monograph does not list — arising from DRAFT-PT-141-MONOG/017. The synonym list is extended to include every name the Institute can evidence from a document it holds, each recorded with its source. Names asserted without a supporting document are not added, and the distinction is stated at the head of the list.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.